依柯胰岛素治疗2型糖尿病的快速卫生技术评估

打开文本图片集

中图分类号R977.1+5 文献标志码A 文章编号1001-0408（2025）22-2856-06

DOI 10.6039/j.issn.1001-0408.2025.22.18

ABSTRACTOBJECTIVETocomprehensively evaluate theeficacy，safetyandcost-effectivenessof insulinicodec ntreating type2diabetesmelitus（T2DM），providingevidence-basedguidancefornewdrugselectioninhospitalandclinicalmedication decision-making.METHODSPubMed，Cochrane Library，Embase，CNKI，Wanfang，VIPandforeign health technology assessment（HTA）websites weresearchedbyusing rapidhealth technologyassssment frominception to15July 2025 for systematicreviews/meta-analyses，pharmacoeconomicstudies，andHTAreportsoninsulinicodecinthetreatmentofT2DM.After dataextractionandqualityassessment，thefindingsoftheincludedstudieswereanalyzeddescriptively.RESULTSTensystematic reviews/meta-analysesandthreepharmacoeconomicstudieswereincluded.Amongthem，4systematicreviews/meta-analyseswere ofhighquality；theoverallqualityofthe3pharmacoeconomicstudiesasrelativelygood.Regardingeficacyinsulinicodecwas superior toonce-dailybasal insulin inreducing glycatedhemoglobin （HbAlc）and inachieving the target of HbAlc <7% （ P<0.05 ） No significant differences were observed between icodec insulinandcomparators in lowering fasting plasma glucose（ （P>0.05 ）.For safety，isulinicodcdidnotincreasetheicidenceofayadverseevents（AEs），seriousAEs，icallsignificanthypoglyea （random glucose <3mmol/L ），injection-site reactions，or allergic reactions，compared with once-daily basal insulin overall （ P> 0.05）；however，insulin icodec was associated with a significant increase in body weight（ ⋅P<0.05 ）.Domestic economic evaluatiosindicatedthatinsulinicodecwasmorecost-efectivethaninsulinglargineandinsulindegludecwhenitsanualcosts wereintherangeof784.90-1145.96and597.66-736.34USdollrs，respectively.CONCLUSIONS Insulin icodec demonstrates favorableeficacyandsafetyprofilesinthetreatmentofT2DM；however，atentionshouldbepaidtotheriskof weightgain.UnderChina's healthcare system，insulin icodec demonstrates greater economicvalue only when the patient's weekly required basal insulin dose fallswithin a specific range，and clinical practice requires individualization.

KEYWORDS insulin icodec； type 2 diabetes mellitus; efficacy；safety；cost-effectiveness；rapid health technology assessment

糖尿病是危害人类健康的慢性病之一，已成为全球公共卫生领域的严峻挑战。（剩余14769字）